I can't say that I knew of any patients who received metformin that weren't diabetic. I saw it used in a number of women who had PCOS (which does have a diabetic component in some patients).

Given the findings of the STAMPEDE trial, I can see its value in prostate cancer patients. Will the addition of metformin to ADT become standard of care? Well, time will tell. We know that ADT has a variety of undesirable metabolic side effects, notably raising blood sugar and cholesterol. Metformin may be a viable addition to ADT if it can safely be used to offset the deleterious effects of ADT. For example, we know that weight is a common issue with ADT. Wouldn't it be beneficial if we could curtail adding poundage with the temporary addition of metformin? Heck, I'm skinny, and still managed to gain eleven pounds over six months of Orgovyx therapy. For someone who's never had any body fat, that was most unpleasing. Fortunately, I've been able to shed some of it.

So, I don't have the ultimate answer to whether we should or shouldn't use it, or whether a doctor will or won't prescribe it. The medical community can make that decision. The data from this study is compelling though.